COVID 19

Managed Supply Services

INTRODUCTION

A key focus as the COVID-19 Pandemic [SARS-Co-V-2; coronavirus disease] continues its surge throughout the world touching every community province, state and country in its path. This pandemic like many before it has placed the heavy burden of assuring the public through businesses, hospitals and governments that they have command over resources for citizens' safety, medical care and supplies, and that they have the ability to maintain critical health care delivery of vital services (e.g., respiratory, surgical, critical care, dialysis etc.).

Health care facilities, providers, businesses and governments do not have the option to avoid or wait and make crisis care decisions when the situation arises. Yet here we are again, with only minimal crisis plans in place. The world is scrambling to get equipment, hoarding supplies, lack of personnel and insufficient budgets to meet demands.

Many facilities, businesses and emergency medical agencies have been waiting on state and government level actions or plans rather than planning at the ground level or health care facility level.

Many hospitals have failed to maximize their conventional (usual customary care) and contingency planning. Nor have they ensured the integration of crisis care into existing surge capacity plans rather they have described such plans as a separate entity, therefore making success elusive. Businesses have found themselves without any Pandemic plan in place for loss of business, remote work or protection of staff to provide continuity of service.

"Extreme surge" (ES), as we are currently facing will subside during the summer and can be expected to return at a far greater level (due to reoccurrence, no vaccine, no medication) between late September and early October according to the World Health Organization. The ES involves significant adaptations of staff, space, supplies and the respective usages must be anticipated and planned.

SanPete Financial Group MOBIMED Division 3500 Lenox Rd N.E., Atlanta, GA 30326
T: +1.832.819.5260 |**E:** info@sanpetefinancialgroup.com |**W:** sanpetefinancialgroup.com

SPFG
"Your Access to Capital"

COVID 19

Managed Supply Services

May 2020

TO WHOM IT MAY CONCERN:

Dear Sir or Madam,

SanPete Financial Groups' MOBIMED Medical Supply Division can assist you with getting your Pandemic Plan in place and with setting up recurring drop shipment of supplies at your designated levels and intervals.

Managing your supply shipment will save you time, budgetary concerns and give you total control of your inventory.

We can help to ensure that you are able to provide consistency of safe environments, health care and good community service to all citizens and to primarily provide you peace of mind during any ensuing pandemic or disastrous event.

We look forward to working with you and your teams to provide the COVID 19 medical supplies and equipment you require.

Warm Regards,

Yvonne E. Gamble

Chief Executive Officer

cc.
Gwendolyn Hinton
VP Finance & Client Services

SanPete Financial Group MOBIMED Division 3500 Lenox Rd N.E., Atlanta, GA 30326
T: +1.832.819.5260 |**E:** info@sanpetefinancialgroup.com |**W:** sanpetefinancialgroup.com

SPFG
"Your Access to Capital"

COVID 19

Managed Supply Services

COVID 19

PRODUCT COMPLIANCE

All products are shipped direct from the United States, China and the United Kingdom, and are FDA approved and C.E. certified.

MEDICAL SUPPLY GENERAL PROCEDURES

1. Send Letter of Intent, item number, quantity and compliance spec for each item.
2. Show Proof of Funds. Discuss Terms, Conditions and Freight Costs.
3. We will prepare Purchase Order specifications based on products. We will provide FDA and C.E. Certifications.
4. Sign required documents, remit required payment (50% minimum down).
5. Your shipment will be tracked with notification of delivery.

SanPete Financial Group MOBIMED Division 3500 Lenox Rd N.E., Atlanta, GA 30326
T: +1.832.819.5260 |**E:** info@sanpetefinancialgroup.com |**W:** sanpetefinancialgroup.com

CORONAVIRUS
MED SUPPLIES
WE WANT YOU SAFE & HEALTHY

HAND SANITIZERS

FLUID RESISTANT SURGICAL MASK W/SHIELD

KN95 MASKS

GLOVES



EMAIL ORDER

Rosette Aliu - newedrac@yahoo.com +233 24 459 8017
Ency Litsoane - ency@ubambano.org.za +27 83 235 0859
Yvonne Gamble - info@sanpetefinancialgroup.com +1.832.819.5260

All Products
FDA or C.E. Certified
+1.832.819.5260

See Our Supply List

CORONAVIRUS MEDICAL SUPPLIER CATALOGUE

SANQUI Medical & Health Minimum Order 200,000	**N95**	**Particulate Respirator FDA & CE 99.6% Certified**	$3.60 ea;	
3M 1860 Minimum Order 500,000	3M 1860	Surgical Mask NIOSH Approved: N95. Meets CDC guidelines FDA >99% BFE (Fluid resistant)	$2.70 ea.	
PRUNUS Minimum Order Based on model See Specifications	Boaray 5000D	Boaray 5000D Ventilator 20-2000ml (VCV); Applicable to adult, pediatric and infant	$25,000 – $75,000 Based on Model	
Minimum Order 20,000	RBE-57	Canister RBE-57, Hood 6 EA/Case	$56.58 ea; 6 per case	
Leading Chinese Manufacturer **Minimum Order 500,000**	Nitrile Gloves	**Disposable Nitrile Gloves, 6 Mil / 100 Pack**	$12.00 per 100 Pack	

STRICTLY CONFIDENTIAL

Leading US and Chinese Manufacturers

Manufacturer	Model Number	Description	Pricing	Product Image
Leading US Manufacturer Minimum Order 500	IDC/GAF 4630000	PPE Goggles	$10 - $150	
Leading Chinese Manufacturer Minimum Order 500,000	Nitrile Gloves	Disposable Nitrile Gloves	$12.00 box; 100 gloves per box	
Minimum Order 1,000,000	K1840	3M High Fluid Resistant Procedure Mask, Ear Loop level 3	$0.25 ea; 50 per box	
Minimum Order 500,000	Hand Sanitizer	Instant Hand Antiseptic 75% Ethyl Alcohol 500 ml	$6.90 ea	
Minimum Order 10 •10 +US $65.21 •20+US $63.27 •50+ US $61.27 •100+ US 59.27 •150+ US $53.27	Handheld Non-Contact	Non-Contact Digital Thermometer-Forehead Laser Infrared	$25.00 ea 10,000 minimum	

SinoPharm and Smartmatic Products

Item	Min.Order	Cost/Unit	Product Image
KN 95 (CE Mark - WKH KANGBANG FFP2 Certified Particulate filter to 99.6%	50,000	$3.25	
Surgical 3 Ply Mask YY0469-2011 Standard Similar to EN16683 Type 1, with Fluid Resistance like Type 3	50,000	$0.75	
Quick Test Kit US Based Manufacturer See Specifications	1,000,000	$30.00	
Sterile Gloves (pair)	2,000,000	$0.18	
Hand Sanitizer # PB128 - 8oz	1,000,000	$3.60	
Hand Sanitizer - 32oz (1L)	1,000,000	$14.40	

STRICTLY CONFIDENTIAL

Hand Sanitizer - 20L Refill	1,000,000	$72.00	
"Thermometer - Digital Forehead"	20,000	$38.00	
Full body "Tyvek" See Specifications	20,000 25 per box	$20.00	
Level 3/4 surgical gown	20,000	$30.00	
Isolation Gowns	20,000	$16.00	

prunus

Your Most Reliable Healthcare Solution Provider



Boaray 5000D Ventilator

- 20-2000ml (VCV); Applicable to adult, pediatric and infant
- Various ventilation modes for different needs of all patients
- 15 inch TFT touch screen & big font view for easy observation
- Touch screen & Navigation knob for simple operation
- Simultaneous display of 4 waveforms and 2 loops
- Optional CO_2 monitoring helps verity correct intubation and stability of metabolism
- Optional SpO_2 monitoring avoids deficiency of oxygen
- Synchronized nebulizer (optional)
- Low noise and water-free medical air compressor (optional)
- Expiratory valve could be taken off for autocalvable disinfection to avoid cross-infection
- Active exhalation valve with anti condensation design
- World leading brands of key components of ventilator ensure high accuracy and stable performance
- Advanced proportional solenoid technology realize accurate ventilation control
- Multi-safety mechanism and three-priority alarm of visual and audio for different risks

CE 0123

Specification	Boaray5000D
Patient type:	Adult, Pediatric and infant（≥5kg）
Ventilation modes:	VCV, PCV, SIMV(V)+PS, SIMV(P)+PS, SPONT/CPAP, Sigh
	PRVC, DualPAP, NPPV, Manual , Standby,
Tidal Volume:	20-2000 mL
Ventilation frequency:	1-100 bpm
Inspiration time:	0.1-10S (increment:0.1S)
FiO_2:	21%-100%
Flow trigger:	0.5-20L/Min
Pressure trigger:	-20-0cmH_2O
Pressure control:	5-70 cm H_2O
Pressure support:	0-70 cm H_2O
Electronic PEEP:	0-50 cm H_2O (increment: 1 cm H_2O)
Nebulizer:	30 minutes
Direct access function:	100% O_2 2 min, Inspiration hold, Expiration hold, Manual, Freeze, Lock
Monitoring:	Volume:V_{TI}, V_{TE}, MV, MVspont. Pressure:Ppeak, Pmean, Pplat, Pmin, PEEP,Freq
	Fspont, I:E, FiO_2, Compliance, Resistance, RSB, P0.1, NIF, Auto PEEP, Rcexp,Cdyn
	Co_2 module (optional): $EtCO_2$
	SpO_2 module (optional): SpO_2, PR
Waveform:	P-T, F-T, V-T, Optional: SpO_2-T, $EtCO_2$-T
Loop:	P-V, F-V, F-P, Optional: Volume-$EtCO_2$
Trend:	Peak, FiO_2, PEEP, MV, V_{TE}, V_{TI}
System Log:	500 events (setting and alarm)
Alarm:	Audio and visual alarms with three levels
	Volumes: V_{TE} high/low, MV high/low; Pressure: Paw high/low
	O_2 supply pressure high/low, Air supply pressure high/low
	Apnea, Continuous high airway pressure
	Freq high/low, FiO_2 high/low
	SpO_2 low (optional), $EtCO_2$ high/low (optional)
	Power: AC power failure, Low battery power, Exhausted battery failure

Physical Specification	
Dimensions (H×W×D):	Host:645*735*610(mm) Trolley:225*805*555(mm)
Communication Interface:	RS232
Screen:	15 inch TFT touch screen
Net weight:	Host:45kg,Trolley:22.5kg
Power:	100-240VAC, 50/60Hz, 1A(Max)
Lithium Battery:	Minimum 120 minutes

Full Body Tyvek Specifications

Technical Data Sheet

Brand Name:	Derma Care
Product Name:	Coveralls
Code:	MT-428
Description:	Disposable Coverall With Hood And Elastic Cuff
Color:	White
Approvals	SGS
Standards	

EN ISO 14325:2004 Protective clothing- general requirements.

EN 1149-1:2006

EN 13034:2005 Protective clothing against liquid chemicals- Performance requirements for chemical protection clothing offering limited protective performance against liquid chemicals

EN ISO 13982- 1:2004+ Protective clothing for use against solid particulates-Part1: Performance requirements for chemical protective clothing providing protection to the full body against airborne solid particulates

Coronavirus (COVID-19) Instant Test Kits for Medical Professional Use

- Rapid results in 10 minutes
- Small sample sizes
- Sold in packs of 100
- Following the incubation period, IgM may appear in blood within 3-5 days. IgG will appear as soon as 1-2 weeks.
- Shelf life of 24 months from manufacture date
- Forensic / Medical Professional Use Only
- Tests should be conducted by a licensed phlebotomist, or a medical professional
- Verification of use case prior to shipping is mandatory

Warning: This Coronavirus instant test kit has not been reviewed by the FDA and results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

RAPID ANTIBODY TEST

Understanding the Emergency Use Authorization PEUA-200094, and our Antibody test FDA Registered Establishment Number 2031229. Made in AMERICA COVID-19 Rapid Test.

Dr. Stephen Hahn, Director FDA KNOW YOUR TESTS:

- What test is it
- What is the process
- Where is it manufactured
- What are the reagents
- Where are reagents manufactured
- What is the cross reactivity
- What is the sensitivity rating
- What are the requirements
- What is the total cost
- What is the test application time investment
- Does the test have a CPT code process
- Is the test eligible for insurance reimbursement

We offer the COVID-19 finger prick antibody 5-10 minute test now. We also offer the Molecular test through mail in or CLIA certified POC machine. This cartridge has been deployed in use for the intended goal of a quick, easy, efficient, and AFFORDABLE test to the mass public, for the 80% that will NOT require further treatment or testing.

Simple, fast, efficient, accurate:



The COVID19 IgG/IgM Rapid Test

The COVID19 IgG/IgM Rapid Test is a 10-minute instant point-of-care test device for the qualitative detection of IgG and IgM antibodies specific to 2019-nCoV in human whole blood, serum or plasma specimens.

IMPORTANT

- This test is pending review by the FDA.
- This test is not for the screening of donated blood.
- This test is for research use only or for emergency use during the COVID19 pandemic.

INTENDED USE

The COVID19 IgG/IgM Rapid Test Cassette is intended to be used in conjunction with other test and/or clinical and epidemiological information:

- For the in vitro qualitative detection of IgM and IgG antibodies specific to 2019n-CoV (detected in China in 2019) in whole blood / serum / plasma collected directly from symptomatic patients. The test **may** cross react with other viruses not being tested.
- For the presumptive identification of viral infections in patients who may be infected with 2019nCoV (detected in China in 2019) in conjunction with clinical and epidemiological risk factors. The test **may** cross react with other viruses not being tested.
- To provide **epidemiologic information** for surveillance of 2019n-CoV (detected in China in 2019)

Testing with the COVID19 IgG/IgM Rapid Test Cassette should **only** be performed **in conjunction with** other laboratory approved testing and/or clinical observations for the presumptive identification of viral infections in patients who may be infected with 2019nCoV (detected in China in 2019).

NOTE: The USFDA updated their guidance, issued on March 16, 2020, to allow the distribution of this product for diagnostic use in laboratories or by healthcare workers at point-of-care facilities.

All test results are presumptive and should be confirmed by an approved molecular assay. A presumptive negative test does not preclude 2019n-CoV infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, a presumptive positive result does not rule out infections caused by other viruses.

ABOUT THE TEST AND COVID 19 (2019nCoV)

In response to the global pandemic caused by 2019n-CoV, the COVID19 lgG/lgM Rapid Test Cassette was developed as a 10-minute simple field test using a lateral flow immunoassay that will allow field personnel with minimal training to perform. The test detects the presence of lgG and lgM antibodies specific to 2019n-CoV (detected in China in 2019) generally available in whole blood/ serum / plasma after infection by 2019n-CoV.

Early January 2020, a novel coronavirus (2019-nCoV) was identified as the infectious agent causing an outbreak of viral pneumonia in China, where the first cases had their symptom onset in December 2019.1

Coronaviruses are enveloped RNA viruses that are distributed broadly among humans, other mammals, and birds and that cause respiratory, enteric, hepatic, and neurologic diseases.2 Six coronavirus species are known to cause human disease.1 Four viruses - 229E, OC43, NL63, and HKU1 - are prevalent and typically cause common cold symptoms in immunocompetent individuals.1 The two other strains - severe acute respiratory syndrome coronavirus (SARS-COV) and Middle East respiratory syndrome coronavirus (MERS-COV) - are zoonotic in origin and have been linked to sometimes fatal illness.4

Coronaviruses are zoonotic, which means they can be transmitted between animals and people. Common signs of infection include respiratory symptoms, fever, and cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death.5

Standard recommendations to prevent infection spread include regular hand washing, covering mouth and nose when coughing and sneezing, thoroughly cooking meat and eggs. Avoid close contact with anyone showing symptoms of respiratory illness such as coughing and sneezing. 5

HOW THE TEST WORKS

In response to the global pandemic caused by 2019n-CoV (COVID19), the COVID19 lgG/lgM Rapid Test Cassette was developed as a 10-minute simple field test using a lateral flow immunoassay that will allow field personnel with minimal training to perform. The test detects the presence of lgG and lgM antibodies specific to 2019n-CoV {detected in China in 2019) generally available in whole blood/ serum/ plasma after infection by 2019n-CoV.

The COVID19 lgG/lgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative membrane- based, lateral flow immunoassay for the detection of lgG and lgM antibodies to 2019-nCoV in whole blood, serum or plasma specimen. This test consists of two components, an lgG component and an lgM component.

In the lgG component, anti-human lgG is coated in the lgG test line region on the membrane. During testing, when the specimen is added to the test cassette, it reacts with 2019-nCoV antigen-coated particles inside the test cassette. The mixture then migrates upward on the membrane chromatographically by capillary action and reacts with the anti-human lgG coated in the lgG test line region. If the specimen contains lgG antibodies to 2019-nCoV, a complex will be formed resulting in a colored line that will appear in the lgG test line region. Similarly, anti-human lgM is coated in the lgM test line region and if the specimen contains lgM antibodies to 2019-nCoV, the conjugate-specimen complex reacts with anti-human lgM on the membrane. A colored line appears in lgM test line region as a result.

Therefore, if the specimen contains 2019-nCoV lgG antibodies, a colored line will appear in lgG test line region. If the specimen contains 2019-nCoV lgM antibodies, a colored line will appear in lgM test line region. If the specimen does not contain 2019-nCoV antibodies, no colored line will appear in either of the test line regions, indicating a negative result. To serve as a procedural control, a colored line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred, and the test has been activated correctly.

THE REAGENTS

The test contains anti-human lgM and anti-human lgG as the capture reagent, 2019-nCoV antigen as the detection reagent. A goat anti-mouse lgG is employed in the control line system.

PRECAUTIONS

1. **Biohazard.** Biological samples such as blood have the potential to transmit infectious diseases. Follow all applicable local, state, and federal regulations.
2. Use routine laboratories precautions. Do not eat, drink or smoke in the area where the specimens or kits are handled.
3. Do not use the test if protective pouch is damaged.
4. For research use only. Do not use after expiration date.
5. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout all procedures and follow the standard procedures for proper disposal of specimens.
6. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
7. Please ensure that an appropriate amount of samples are used for testing. Too much or too little of sample size may lead to deviation of results.
8. Used test should be discarded according to local regulations.
9. Humidity and temperature can adversely affect results.

STORAGE AND STABILITY

Store as packaged in the sealed pouch at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

PROCEDURE

SPECIMEN COLLECTION AND PREPARATION FOR TESTING

The COVID19 lgG/lgM Rapid Test Cassette (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or finger prick), serum or plasma.

To collect Finger prick Whole Blood Specimens (when ready to perform the test):

- Wash the patient's hand with soap and warm water or clean with an alcohol swab. Allow to dry.
- Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
- Puncture the skin of 1 finger with a sterile lancet. Wipe away the first sign of blood.
- Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
- Collect the blood from the finger using the dropper provide or by using a capillary tube.
- Transfer the blood specimen to the sample well on the test device

To collect Whole Blood using Venipuncture and preparation of Serum and Plasma:

- Collect blood using general guideline for venipuncture.
- Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear non-hemolyzed specimens.

Testing Preparation

- Testing should be performed immediately after the specimens have been collected.
- Do not leave the specimens at room temperature for prolonged periods.
- Serum and plasma specimens may be stored at 2-8°C for up to 7 days, for long term storage, serum/plasma specimens should be kept below -20°C.
- Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens.
- Whole blood collected by finger prick should be tested immediately.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with local regulations.
- EDTA K2, Heparin sodium, Citrate sodium and Potassium Oxalate can be used as the anticoagulant for collecting the specimen.

RUNNING THE TEST

Allow the test, specimen, buffer and/or controls to reach room temperature (15-30°C) prior to testing.

1. Remove the test cassette from the foil pouch and use it within one hour. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Place the cassette on a clean and level surface.

For **Serum or Plasma** specimen:

- To use a dropper: Hold the dropper vertically, draw the specimen to the **fill line** (approximately 10µL), and transfer the specimen to the specimen well **(S),** then add **2 drops of buffer** (approximately 80 µL), and start the timer.
- To use a pipette: Transfer **10 µL** of specimen to the specimen well(S), then **add 2 drops of buffer** (approximately 80 µL), and start the timer

For **Venipuncture Whole Blood** specimen:

- To use a dropper: Hold the dropper vertically, draw the specimen about **1 cm above the fill line** and transfer **1 full drop** (approx. 20µL) of specimen to the sample well(S). Then add **2 drops of buffer** (approximately 80 µL) and start the timer.
- To use a pipette: Transfer **20 µL** of whole blood to the specimen **well(S),** then **add 2 drops of buffer** (approximately 80 µL), and start the timer

For **Finger prick Whole Blood** specimen:

- To use a dropper: Hold the dropper vertically, draw the specimen about **1 cm above the fill line** and transfer **1 full drop** (approx. 20µL) of specimen to the sample **well(S).** Then add **2 drops of buffer** (approximately 80 µL) and start the timer.
- To use a capillary tube: Fill the capillary tube and transfer **approximately 20µL of finger prick whole blood specimen** to the specimen well **(S)** of test cassette, then **add 2 drops of buffer** (approximately 80 µL) and start the timer. See illustration below.

Wait for the colored line(s) to appear. **Read results at 10 minutes.** Do not interpret the result after 20 minutes.

Note: It is suggested not to use the buffer beyond 6 months after opening the vial.

Internal procedural controls are includ (C) is an internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The COVID19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is for in vitro diagnostic use only. This test should be used for detection of IgG and IgM antibody to 2019-nCoV in whole blood, serum or plasma specimens. Neither the quantitative value nor the rate of increase in the concentration of IgG or IgM antibodies to 2019-nCoV can be determined by this qualitative test.
2. The COVID19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma) will only indicate the presence of IgG and IgM antibodies to 2019-nCoV in the specimen and should not be used as the sole criteria for the diagnosis of 2019-nCoV infections.
3. As with all diagnostic tests, all results must be considered with other clinical information available to the physician.
4. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is suggested. A negative result at any time does not preclude the possibility of 2019-nCoV infection.
5. The hematocrit level of the whole blood can affect the test results. Hematocrit level needs to be between 25% and 65% for accurate results.
6. The test will show negative results under the following conditions: The titer of the novel coronavirus antibodies in the sample is lower than the minimum detection limit of the test, or the novel coronavirus antibody has not appeared at the time of sample collection (Asymptomatic stage).

PERFORMANCE CHARACTERISTICS

Clinical Performance

The clinical performance of the "*COVID19 IgG/IgM Rapid Test Cassette*" was evaluated in Shanghai, China with clinical samples derived from blood samples collected from 2019n-CoV infectious patients and 2019n-CoV non-infectious patients confirmed by PCR.

The study included testing of 20 known positive samples and 50 known negative samples.

Of the 20 known positive samples, the IgG test yields a 100% agreement of 20 out of 20, while the IgM test yields an 85% agreement of 17 out of 20.

Of the 50 known negative samples, the IgG test yields a 98% agreement of 49 out of 50, while the IgM test yields a 96% agreement of 48 out of 50. The data are illustrated in the table below.

Sensitivity and Specificity

IgG Result

Method		**PCR**		**Total Results**
	Results	**Positive**	**Negative**	
2019-nCoV IgG/IgM Rapid Test	Positive	20	1	21
	Negative	0	49	49
Total Result		20	50	70

IgG test results yields 20 positive results from 20 know positive samples.

IgG test results yields 49 negative samples from 50 known negative samples.

Relative Sensitivity: 100% (95%CI*: 86.0%-100%) *Confidence Interval

Relative Specificity: 98.0% (95%CI*: 89.4%-99.9%)

Accuracy: 98.6% (95%CI*: 92.3%-99.96%)

IgM Result

Method		**PCR**		**Total Results**
	Results	**Positive**	**Negative**	
2019-nCoV IgG/IgM Rapid Test	Positive	17	2	19
	Negative	3	48	51
Total Result		20	50	70

IgM test results yields 17 positive results from 20 know positive samples.

IgG test results yields 48 negative samples from 50 known negative samples.

Relative Sensitivity: 85.0% (95%CI*: 62.1%-96.8%) *Confidence Interval

Relative Specificity: 96.0% (95%CI*: 86.3%-99.5%)

Accuracy: 92.9% (95%CI*: 84.1%-97.6%)

Cross-reactivity

The "*COVID19 IgG/IgM Rapid Test Cassette*" (Whole Blood/Serum/Plasma) has been tested against anti-influenza A virus, anti-influenza B virus, anti-RSV, anti-Adenovirus, HBsAg, anti-Syphilis, anti-H. Pylori, anti-HIV and anti-HCV positive specimens. The results showed no cross-reactivity.

Interfering Substances

The following compounds have been tested using the 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) and no interference was observed.

- Triglyceride: 50 mg/dL - Ascorbic Acid: 20mg/dL - Hemoglobin: 1000mg/dL-
Bilirubin: 60mg/dL - Total cholesterol : 6mmol/L

Supporting videos:

- https://www.youtube.com/watch?time_continue=4&v=DH-RXIeVQXY&feature=emb_logo
- https://www.youtube.com/watch?v=tVKUK5RzW8E&feature=emb_logo

Our tests as compared to other tests available. Others available upon request.

BIBLIOGRAPHY

1. *World Health Organization (WHO). WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Beijing: WHO; 9 Jan 2020. [Accessed 26 Jan 2020].* https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china
2. *Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85-164.*

PMID:22094080 DOI:10.1016/B978-0-12-385885-6.00009-2

1. *Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502.*

PMID:27012512 DOI:10.1016/j.tim.2016.03.003

1. *Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-192.PMID:30531947 DOI:10.1038/s41579-018-0118-9*
2. *World Health Organization (WHO).* Corona*virus.* https://www.who.int/health-topics/coronavirus

SPFG
"Your Access to Capital"

Order Process

Send Letter of Intent, item number, quantity and compliance spec for each item.

Show Proof of Funds.
Discuss Terms, Conditions, Freight Costs.

We will prepare P.O. specifications based on products. We will provide FDA or C.E. Certifications.

Sign required documents, remit required payment.

Your shipment will be tracked with notification of delivery.

Order Process

SHIPPING

Freight Delivered ONLY to your address. Shipment 3 - 6 weeks from date of order.

Freight charges will appear in Terms & Conditions.

All orders will be shipped to the address you provide.

RETURN AND REFUND POLICY

Return and Refund policy, based on Manufacturers Policy.

Please contact manufacturer to facilitate return and refund.

SPFG
"Your Access to Capital"

FIND US ON

facebook.com/sanpetefinancialgroup

USA Yvonne Gamble +1.832.819.5260
GHANA Rossette Aliu +233 24 459 8017
SOUTH AFRICA Ency Litsoane +27 83 235 0859

twitter.com/sanpetegrp

USA Yvonne Gamble info@sanpetefinancialgroup.com
GHANA Rossette Aliu newedrac@yahoo.com
South Africa Ency Litsoane ency@ubambano.org.za

sanpetefinancialgroup.com